deltatrials
Active Not Recruiting PHASE2 INTERVENTIONAL 2-arm NCT00859781

177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer

A Randomized Phase 2 Trial of 177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With High-Risk Castrate Biochemically Relapsed Prostate Cancer After Local Therapy

Sponsor: United States Department of Defense

Conditions Prostate Cancer
Interventions 111In-J591 177Lu-J591 Hydrocortisone Ketoconazole
Updated 16 times since 2017 Last updated: Apr 23, 2025 Started: Jun 30, 2009 Primary completion: Feb 10, 2022 Completion: May 31, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00859781, this PHASE2 trial focuses on Prostate Cancer and remains ongoing. Sponsored by United States Department of Defense, it has been updated 16 times since 2009, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Feb 2019 · 7 months · monthly snapshot~Feb 2019 – ~Mar 2020 · 13 months · monthly snapshot~Mar 2020 – ~Jan 2021 · 10 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Apr 2021 · 31 days · monthly snapshot~Apr 2021 – ~Apr 2022 · 12 months · monthly snapshot~Apr 2022 – ~Aug 2023 · 16 months · monthly snapshot~Aug 2023 – ~Jun 2024 · 10 months · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~May 2025 · 8 months · monthly snapshot~May 2025 – ~Sep 2025 · 4 months · monthly snapshot~Sep 2025 – present · 9 months · monthly snapshot

Change History

16 versions recorded

  1. Sep 2025 — Present [monthly]

    Active Not Recruiting PHASE2

  2. May 2025 — Sep 2025 [monthly]

    Active Not Recruiting PHASE2

  3. Sep 2024 — May 2025 [monthly]

    Active Not Recruiting PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2

  5. Jun 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

▶ Show 11 earlier versions

  1. Aug 2023 — Jun 2024 [monthly]

    Active Not Recruiting PHASE2

  2. Apr 2022 — Aug 2023 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  3. Apr 2021 — Apr 2022 [monthly]

    Recruiting PHASE2

  4. Mar 2021 — Apr 2021 [monthly]

    Recruiting PHASE2

  5. Jan 2021 — Mar 2021 [monthly]

    Recruiting PHASE2

  6. Mar 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  7. Feb 2019 — Mar 2020 [monthly]

    Recruiting PHASE2

  8. Jul 2018 — Feb 2019 [monthly]

    Recruiting PHASE2

  9. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE2

  10. Feb 2017 — Jun 2018 [monthly]

    Recruiting PHASE2

  11. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE2

    First recorded

Jun 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • United States Department of Defense
  • Weill Medical College of Cornell University
Data source: Weill Medical College of Cornell University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations